IL17A and metabolic dysfunction-associated steatohepatitis: Inhibiting IL-17 signaling has been shown to reduce Kupffer cell activation and decrease the levels of pro-inflammatory cytokines, providing further evidence for the pro-inflammatory role of Th17 cells in the pathogenesis of NASH (60).